MedTech Innovator Announces 2023 Grand Prize Finalists
Duke start-up Sparta Biomedical has been selected as one of five AdvaMed Accel and MedTech Innovator Execution Award Finalists.
Setting Rivalries Aside, University Startups Come Together to Pitch 50+ Elite Investors at Triangle Venture Day: Therapeutics 2023
The recurring event offers venture capital investors from across the country an exclusive look at therapeutics startups launching from Duke, UNC, NC State University, and the North Carolina Biotechnology Center.
Durham-based Restor3d raises $17 million
restor3d, a Duke spinout from the lab of Prof Ken Gall (MEMS, Pratt), is also a Duke Capital Partners portfolio company.
Aspirion Acquires Infinia ML, an established leader in AI and Machine Learning
Infinia ML is a Duke artificial intelligence start-up spun out of the lab of Professor Lawrence Carin (ECE, Pratt).
Sparta Biomedical Closes an Oversubscribed Convertible Round to Advance its Breakthrough Device
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…
Pivotal Commware Raises $102 million Series D Round to Accelerate mmWave Wireless FWA Rollout
Pivotal Commware is a Duke start-up co-founded by Professor David Smith (ECE, Pratt).
NCBiotech Awards $2.75 Million in Grants, Loans in Latest Quarter
Two Duke start-ups received loans & four Duke projects received Translational Research Grants. Recipients hail from across the university!
Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Precision BioSciences, a genome editing Duke spin-out, was founded by then-postdocs Jeff Smith and Derek Jantz (Biochemistry, SOM).